The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Prosvetov A.O.

Evdokimov Moscow State University of Medicine and Dentistry

Tsygankov B.D.

Evdokimov Moscow State University of Medicine and Dentistry

Guekht A.B.

Solov’ev Research and Clinical Center for Neuropsychiatry

Kuznetsov E.V.

Evdokimov Moscow State University of Medicine and Dentistry

Less U.E.

Moscow Research and Clinical Center for Neuropsychiatry

Tumurov D.A.

Solovyov Scientific and Practical Psychoneurological Center

Popov G.R.

Moscow Research and Clinical Center for Neuropsychiatry

Tsygankov D.B.

Institute of Mental Health and Addictology

Rangus S.R.

Evdokimov Moscow State University of Medicine and Dentistry

Transcranial magnetic stimulation in the treatment of depressive disorder in Parkinson’s disease

Authors:

Prosvetov A.O., Tsygankov B.D., Guekht A.B., Kuznetsov E.V., Less U.E., Tumurov D.A., Popov G.R., Tsygankov D.B., Rangus S.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(9): 79‑85

DOI: 10.17116/jnevro202212209179

Read: 2522 times

Download PDF (RU)
Contact the author
Table of contents

TRANSCRANIAL MAGNETIC STIMULATION IN THE TREATMENT OF DEPRESSIVE DISORDER IN PARKINSON’S DISEASE
TRANSCRANIAL MAGNETIC STIMULATION IN THE TREATMENT OF DEPRESSIVE DISORDER IN PARKINSON’S DISEASE

To cite this article:

Prosvetov AO, Tsygankov BD, Guekht AB, et al. . Transcranial magnetic stimulation in the treatment of depressive disorder in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(9):79‑85. (In Russ.)
https://doi.org/10.17116/jnevro202212209179

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Clinical presentation and diagnosis of Parkinson’s disease in patients with schi­zophrenia spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):73-80
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99
Chro­nic epidural spinal cord stimulation for gait impairments in Parkinson’s disease and atypical parkinsonism. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):100-112
A portrait of a doctor with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):160-164
The asso­ciation of NOS1AP gene poly­morphisms with the dura­tion of the QT inte­rval in patients with schi­zophrenia receiving anti­psychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104
Pathomorphosis of the Parkinson’s disease against the background of DBS STN. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):21-27
Transcranial magnetic stimulation in visual snow syndrome and functional diso­rders of visual perception. Russian Journal of Pain. 2025;(1):46-54
Abstract:

The prevalence of affective disorders in patients with Parkinson’s disease (PD) is significantly higher than in the general population of people of the same age. It is known that the effectiveness of antidepressants in PD with depressive disorder is lower than in patients with primary depression. For depression resistant to standard treatments, other therapeutic strategies are available. Transcranial magnetic stimulation (TMS) is one of the most popular and safe brain stimulation methods that has been successfully used to treat primary depression. The accumulation of experience in the use of TMS has made it possible to expand the application of the method to other diseases, including PD. The article provides literature data on the use of different TMS protocols for the treatment of depressive disorder in patients with PD.

Keywords:

Parkinsons disease
affective disorders
depressive disorder
therapy
transcranial magnetic stimulation

Authors:

Prosvetov A.O.

Evdokimov Moscow State University of Medicine and Dentistry

Tsygankov B.D.

Evdokimov Moscow State University of Medicine and Dentistry

Guekht A.B.

Solov’ev Research and Clinical Center for Neuropsychiatry

Kuznetsov E.V.

Evdokimov Moscow State University of Medicine and Dentistry

Less U.E.

Moscow Research and Clinical Center for Neuropsychiatry

Tumurov D.A.

Solovyov Scientific and Practical Psychoneurological Center

Popov G.R.

Moscow Research and Clinical Center for Neuropsychiatry

Tsygankov D.B.

Institute of Mental Health and Addictology

Rangus S.R.

Evdokimov Moscow State University of Medicine and Dentistry

Received:

14.03.2022

Accepted:

15.03.2022

Close metadata

References:

  1. Tysnes O, Storstein A. Epidemiology of Parkinson’s disease. Journal of Neural Transmission. 2017;124(8):901-905.  https://doi.org/10.1007/s00702-017-1686-y
  2. Parkinson J. An Essay on Shaking Palsy. London: Sherwood, Neeley and Jones; 1817.
  3. Randver R. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex to alleviate depression and cognitive impairment associated with Parkinson’s disease: A review and clinical implications. Journal of the Neurological Sciences. 2018;393:88-99.  https://doi.org/10.1016/j.jns.2018.08.014
  4. von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson’s disease in Europe. European Neuropsychopharmacology. 2005;15(4):473-490.  https://doi.org/10.1016/j.euroneuro.2005.04.007
  5. de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson’s disease in the elderly: The Rotterdam Study. Neurology. 1995;45(12):2143-2146. https://doi.org/10.1212/wnl.45.12.2143
  6. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. The Lancet Neurology. 2006;5(6):525-535.  https://doi.org/10.1016/s1474-4422(06)70471-9
  7. Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clinics in Geriatric Medicine. 2020;36(1):1-12.  https://doi.org/10.1016/j.cger.2019.08.002
  8. Sung VW, Nicholas AP. Nonmotor Symptoms in Parkinson’s Disease. Neurologic Clinics. 2013;31(3):S1-S16.  https://doi.org/10.1016/j.ncl.2013.04.013
  9. Chaudhuri KR, Yates L, Martinez-Martin P. The non-motor symptom complex of Parkinson’s disease: A comprehensive assessment is essential. Current Neurology and Neuroscience Reports. 2005;5(4):275-283.  https://doi.org/10.1007/s11910-005-0072-6
  10. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson’s disease. Movement Disorders. 2001;16(3):507-510.  https://doi.org/10.1002/mds.1099
  11. Simuni T, Sethi K. Nonmotor manifestations of Parkinson’s disease. Annals of Neurology. 2008;64(S2):65-80.  https://doi.org/10.1002/ana.21472
  12. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology. 2002;59(3):408-413.  https://doi.org/10.1212/wnl.59.3.408
  13. Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson’s disease. Parkinsonism & Related Disorders. 2007;13(6):323-332.  https://doi.org/10.1016/j.parkreldis.2006.12.014
  14. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease: Nms and HRQ O L in Parkinson’s Disease. Movement Disorders. 2011;26(3):399-406.  https://doi.org/10.1002/mds.23462
  15. Hwynn N, Haq IU, Malaty IA, et al. The Frequency of Nonmotor Symptoms among Advanced Parkinson Patients May Depend on Instrument Used for Assessment. Parkinson’s Disease. 2011;2011:1-4.  https://doi.org/10.4061/2011/290195
  16. Gallagher DA, Schrag A. Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiology of Disease. 2012;46(3):581-589.  https://doi.org/10.1016/j.nbd.2011.12.041
  17. Lemke MR, Fuchs G, Gemende I, et al. Depression and Parkinson’s disease. Journal of Neurology. 2004;251(6):vi24-vi27. https://doi.org/10.1007/s00415-004-1606-6
  18. Truong DD, Bhidayasiri R, Wolters E. Management of non-motor symptoms in advanced Parkinson disease. Journal of the Neurological Sciences. 2008;266(1-2):216-228.  https://doi.org/10.1016/j.jns.2007.08.015
  19. Schrag A, Taddei RN. Depression and Anxiety in Parkinson’s Disease. International Review of Neurobiology. 2017;133:623-655.  https://doi.org/10.1016/bs.irn.2017.05.024
  20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. fifth. United States: American Psychiatric Publishing; 2013. https://doi.org/10.1176/appi.books.9780890425596
  21. Reijnders JSAM, Ehrt U, Weber WEJ, et al. A systematic review of prevalence studies of depression in Parkinson’s disease. Movement Disorders. 2008;23(2):183-189.  https://doi.org/10.1002/mds.21803
  22. Liu B, Zhang Y, Zhang L, Li L. Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study. BMC Psychiatry. 2014;14(1):1-9.  https://doi.org/10.1186/s12888-014-0342-4
  23. Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biological Psychiatry. 2003;53(8):640-648.  https://doi.org/10.1016/s0006-3223(02)01670-0
  24. Ferrari AJ, Somerville AJ, Baxter AJ, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychological Medicine. 2013;43(3):471-481.  https://doi.org/10.1017/s0033291712001511
  25. George MS, Taylor JJ, Short EB. The expanding evidence base for rTMS treatment of depression. Current Opinion in Psychiatry. 2013;26(1):13-18.  https://doi.org/10.1097/yco.0b013e32835ab46d
  26. Brunoni AR, Chaimani A, Moffa AH, et al. Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes: A Systematic Review With Network Meta-analysis. JAMA Psychiatry. 2017;74(2):143.  https://doi.org/10.1001/jamapsychiatry.2016.3644
  27. Fitzgerald P, Fountain S, Daskalakis Z. A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition. Clinical Neurophysiology. 2006;117(12):2584-2596. https://doi.org/10.1016/j.clinph.2006.06.712
  28. Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biological Psychiatry. 2000;48(8):830-843.  https://doi.org/10.1016/s0006-3223(00)01036-2
  29. Kamble N, Netravathi M, Pal PK. Therapeutic applications of repetitive transcranial magnetic stimulation (rTMS) in movement disorders: a review. Parkinsonism & Related Disorders. 2014;20(7):695-707.  https://doi.org/10.1016/j.parkreldis.2014.03.018
  30. Xie C, Chen J, Wang X, et al. Repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression in Parkinson disease: a meta-analysis of randomized controlled clinical trials. Neurological Sciences. 2015;36(10):1751-1761. https://doi.org/10.1007/s10072-015-2345-4
  31. Machii K, Cohen D, Ramos-Estebanez C, Pascual-Leone A. Safety of rTMS to non-motor cortical areas in healthy participants and patients. Clinical Neurophysiology. 2006;117(2):455-471.  https://doi.org/10.1016/j.clinph.2005.10.014
  32. Dragaševic N, Potrebić A, Damjanović A, et al. Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson’s disease: an open study. Movement Disorders. 2002;17(3):528-532.  https://doi.org/10.1002/mds.10109
  33. Fregni F, Santos CM, Myczkowski ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2004;75(8):1171-1174. https://doi.org/10.1136/jnnp.2003.027060
  34. Epstein CM, Evatt ML, Funk A, et al. An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson’s disease. Clinical Neurophysiology. 2007;118(10):2189-2194. https://doi.org/10.1016/j.clinph.2007.07.010
  35. Pal E, Nagy F, Aschermann Z, et al. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Movement Disorders. 2010;25(14):2311-2317. https://doi.org/10.1002/mds.23270
  36. Lefaucheur J, Andre-Obadia N, Antal A, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clinical Neurophysiology. 2014;125(11):2150-2206. https://doi.org/10.1016/j.clinph.2014.05.021
  37. Brys M, Fox MD, Agarwal S, et al. Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: a randomized trial. Neurology. 2016;87(18):1907-1915. https://doi.org/10.1212/wnl.0000000000003279
  38. Lefaucheur J, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014—2018). Clinical Neurophysiology. 2020;131(2):474-528.  https://doi.org/10.1016/j.clinph.2019.11.002
  39. Lesenskyj AM, Samples MP, Farmer JM, Maxwell CR. Treating refractory depression in Parkinson’s disease: a meta-analysis of transcranial magnetic stimulation. Translational Neurodegeneration. 2018;7(1):1-6.  https://doi.org/10.1186/s40035-018-0113-0
  40. Hai-Jiao W, Ge T, Li-Na Z, et al. The efficacy of repetitive transcranial magnetic stimulation for Parkinson disease patients with depression. International Journal of Neuroscience. 2020;130(1):19-27.  https://doi.org/10.1080/00207454.2018.1495632
  41. Shin H, Youn YC, Chung SJ, Sohn YH. Effect of high-frequency repetitive transcranial magnetic stimulation on major depressive disorder in patients with Parkinson’s disease. Journal of Neurology. 2016;263(7):1442-1448. https://doi.org/10.1007/s00415-016-8160-x
  42. Li S, Jiao R, Zhou X, Chen S. Motor recovery and antidepressant effects of repetitive transcranial magnetic stimulation on Parkinson disease: A PRISMA-compliant meta-analysis. Medicine. 2020;99(18):e19642. https://doi.org/10.1097/MD.0000000000019642
  43. VonLoh M, Chen R, Kluger B. Safety of transcranial magnetic stimulation in Parkinson’s disease: a review of the literature. Parkinsonism & Related Disorders. 2013;19(6):573-585.  https://doi.org/10.1016/j.parkreldis.2013.01.007
  44. Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clinical Neurophysiology. 2009;120(12):2008-2039. https://doi.org/10.1016/j.clinph.2009.08.016
  45. Benninger DH, Berman BD, Houdayer E, et al. Intermittent theta-burst transcranial magnetic stimulation for treatment of Parkinson disease. Neurology. 2011;76(7):601-609.  https://doi.org/10.1212/WNL.0b013e31820ce6bb
  46. Torres F, Villalon E, Poblete P, et al. Retrospective Evaluation of Deep Transcranial Magnetic Stimulation as add-on Treatment for Parkinson’s Disease. Frontiers in Neurology. 2015;6:210.  https://doi.org/10.3389/fneur.2015.00210
  47. Seppi K, Chaudhuri KR, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease — an evidence-based medicine review. Movement Disorders. 2019;34(2):180-198.  https://doi.org/10.1002/mds.27602
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.